-
The Future of Lung Cancer Starts Here
Read time: 1 minute. For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 -
Biggest News from Berlin: Research Highlights from ESMO
Read time: 5 minutes. Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With -
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
Read time: 6 minutes. LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the -
Reaping the Rewards of Radiation to Make Immunotherapy More Effective
Read time: 3 minutes. Immune checkpoint inhibitors (ICIs) have revolutionized the way we approach lung cancer treatment over the past decade. These lifesaving drugs block the PD-L1 -
Aiming for a Cure: How CD74 Research Could Eliminate Drug-Resistant Lung Cancer for Good
Read time: 4 minutes. Lung cancer remains the leading cause of cancer death worldwide. Over the past two decades, the development of targeted therapies, particularly tyrosine -
Researcher Goes Against the Grain: Brings New Hope for Patients with BRAF Fusions
Read time: 4 minutes. BRAF is an important signaling protein that regulates how normal cells grow and multiply through the MAPK (mitogen activated protein kinase) signaling pathway